EVIDENCE PROFILE / PUBLISHED
PT-141 / Bremelanotide
Bremelanotide is a cyclic melanocortin-receptor agonist developed from melanotan-II research; formulation and device are part of the medicine identity. The approved label summarizes placebo-controlled evidence in the defined population; results cannot be generalized to men, postmenopausal women, or other claims.
Evidence at a glance
- Human
- Not rated
- Animal/cell
- Not rated
- Approved medicine
- Approved product existsOne U.S.-approved product, for a specific formulation and use.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Human research examines central melanocortin signaling and sexual-desire outcomes.
Identity
Bremelanotide is a cyclic melanocortin-receptor agonist developed from melanotan-II research; formulation and device are part of the medicine identity.
Biological mechanism or research interest
Human research examines central melanocortin signaling and sexual-desire outcomes.
Verified approved human uses
FDA-approved Vyleesi is a specific subcutaneous autoinjector for acquired, generalized hypoactive sexual desire disorder in premenopausal women under labeled conditions. It is not approved to enhance sexual performance and is not equivalent to this catalogue entry.
Investigational human evidence
The approved label summarizes placebo-controlled evidence in the defined population; results cannot be generalized to men, postmenopausal women, or other claims.
Popular claims versus demonstrated findings
Broad libido, erectile-function, or performance claims exceed the exact labeled population and outcomes.
Human versus animal or cell evidence
Receptor pharmacology supports a mechanism but does not widen the approved indication.
Limitations and known risks
The label includes transient blood-pressure increases, heart-rate decreases, nausea, and potentially persistent focal hyperpigmentation, with cardiovascular contraindications.
